AlphaQuest’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-15,036
Closed -$477K 1823
2025
Q4
$477K Sell
15,036
-59
-0.4% -$1.77K 0.03% 868
2025
Q3
$355K Buy
15,095
+8,802
+140% +$151K 0.02% 1040
2025
Q2
$71.4K Sell
6,293
-4,539
-42% -$43.1K 0.01% 1534
2025
Q1
$72K Buy
+10,832
New +$101K 0.01% 1423
2024
Q4
Sell
-2
Closed -$25 1999
2024
Q3
$25 Sell
2
-2,108
-100% -$29.9K ﹤0.01% 1846
2024
Q2
$28.5K Buy
+2,110
New +$28.5K ﹤0.01% 1251

Other funds holding STOK

AlphaQuest's STOK Position: Q1 2026 in Review

AlphaQuest sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 15,036 shares — an estimated $477K sold.

AlphaQuest first reported a position in STOK in Q2 2024 and held it in 6 quarters. The position peaked at $477K in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • AlphaQuest reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 15,036 Stoke Therapeutics shares in Q1 2026, an estimated $477K.
  • AlphaQuest first reported a position in Stoke Therapeutics in Q2 2024 and held it in 6 quarters.
  • AlphaQuest's Stoke Therapeutics position peaked at $477K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.